Fig. 4.

Elafibranor and S217879 reduce liver inflammation.

Human PCLS were generated from the liver of patients with MAFLD (n = 12) and treated with elafibranor (10 μM) or S217879 (3 μM) or vehicle (DMSO, 0.1%) for 2 days. (A) qPCR analysis of IL-1β and (B) IL-6 expression in human PCLS. (C) Immunoblot analysis of VCAM-1 and (D) ICAM-1 expression in human PCLS. (E) Immunohistochemical analysis of CD68 positive area (%) in human PCLS. Scale bar: 200 μm. Data are expressed as mean ± SEM. ∗p <0.05; ∗∗p <0.01; ∗∗∗p <0.001; ns, not significant (Wilcoxon paired t test). ICAM-1, intercellular adhesion molecule-1; MAFLD, metabolic-associated fatty liver disease; PCLS, precision cut liver slices; qPCR, quantitative PCR; VCAM-1, vascular cell adhesion molecule-1.